BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 16462755)

  • 1. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development.
    Weinstock DM; Ambrossi GG; Brennan C; Kiehn TE; Jakubowski A
    Bone Marrow Transplant; 2006 Mar; 37(6):539-46. PubMed ID: 16462755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J; Einsele H; Gil L; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
    Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
    G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients.
    Merlino C; Cavallo R; Bergallo M; Giacchino F; Bollero C; Negro Ponzi A; Cavallo G
    New Microbiol; 2003 Apr; 26(2):141-9. PubMed ID: 12737195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
    Lee TC; Savoldo B; Barshes NR; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Scott JD; Goss JA
    Clin Transplant; 2006; 20(3):389-93. PubMed ID: 16824159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
    Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
    Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early evidence of lymphoproliferative disorder: post-transplant monitoring of Epstein-Barr infection in adult and pediatric patients.
    Gaeta A; Nazzari C; Verzaro S; Latte MC; Fabri G; Scateni S; Raggi C; Lubrano R; Mancini C
    New Microbiol; 2006 Oct; 29(4):231-41. PubMed ID: 17201089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?
    Greenfield HM; Gharib MI; Turner AJ; Guiver M; Carr T; Will AM; Wynn RF
    Pediatr Blood Cancer; 2006 Aug; 47(2):200-5. PubMed ID: 16206207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
    Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
    Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
    Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation.
    Ahmad I; Cau NV; Kwan J; Maaroufi Y; Meuleman N; Aoun M; Lewalle P; Martiat P; Crokaert F; Bron D
    Transplantation; 2009 Apr; 87(8):1240-5. PubMed ID: 19384173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of Epstein-Barr virus load in Argentinean transplant recipients using real-time PCR.
    Yancoski J; Danielian S; Ibañez J; Turconi A; Cuarterolo M; Zelazko M; Niesters Hubert GM
    J Clin Virol; 2004 Sep; 31(1):58-65. PubMed ID: 15288615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
    Meerbach A; Wutzler P; Häfer R; Zintl F; Gruhn B
    J Med Virol; 2008 Mar; 80(3):441-54. PubMed ID: 18205222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
    Garceau P; Couture C; Cantin B; Bernier V; Sénéchal M
    J Heart Lung Transplant; 2008 Aug; 27(8):928-31. PubMed ID: 18656811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
    Lim WH; Russ GR; Coates PT
    Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
    Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
    J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic EBV gene loads in renal, hepatic, and cardiothoracic transplant recipients as determined by real-time PCR light cycler.
    Leung E; Shenton BK; Green K; Jackson G; Gould FK; Yap C; Talbot D
    Transpl Infect Dis; 2004 Dec; 6(4):156-64. PubMed ID: 15762933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease.
    Carpentier L; Tapiero B; Alvarez F; Viau C; Alfieri C
    J Infect Dis; 2003 Dec; 188(12):1853-64. PubMed ID: 14673764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.